(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-2-nitrophenyl)acetamide

ID: ALA5278653

Max Phase: Preclinical

Molecular Formula: C13H14N4O4

Molecular Weight: 290.28

Names and Identifiers

Canonical SMILES:  CC(=O)Nc1ccc(C2=NNC(=O)C[C@H]2C)cc1[N+](=O)[O-]

Standard InChI:  InChI=1S/C13H14N4O4/c1-7-5-12(19)15-16-13(7)9-3-4-10(14-8(2)18)11(6-9)17(20)21/h3-4,6-7H,5H2,1-2H3,(H,14,18)(H,15,19)/t7-/m1/s1

Standard InChI Key:  LLLDRLNHTMUACB-SSDOTTSWSA-N

Molfile:  

 
     RDKit          2D

 21 22  0  0  0  0  0  0  0  0999 V2000
   29.5784  -10.3962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.5772  -11.2212    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2901  -11.6330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0046  -11.2208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0018  -10.3925    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2883   -9.9845    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8644  -11.6321    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.1522  -11.2201    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4394  -11.6309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.7142   -9.9808    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.4281  -10.3917    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.1369   -9.9811    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.1381   -9.1581    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.4241   -8.7472    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.7090   -9.1594    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.8506   -8.7467    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.9954   -8.7499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1529  -10.3973    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.2920  -12.4602    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   31.0044  -12.8718    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.5794  -12.8715    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  2  7  1  0
  7  8  1  0
  8  9  1  0
 10 11  2  0
 10 15  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
  5 10  1  0
 13 16  2  0
 15 17  1  6
  8 18  2  0
 19 20  2  0
 19 21  1  0
  3 19  1  0
M  CHG  2  19   1  21  -1
M  END

Alternative Forms

1. Parent:

   

   ALA5278653

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 290.28

Molecular Weight (Monoisotopic): 290.1015

AlogP: 1.41

#Rotatable Bonds: 3

Polar Surface Area: 113.70

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.00

CX Basic pKa: 0.66

CX LogP: 0.72

CX LogD: 0.72

Aromatic Rings: 1

Heavy Atoms: 21

QED Weighted: 0.65

Np Likeness Score: -1.27

References

1. Lewis TA, de Waal L, Wu X, Youngsaye W, Wengner A, Kopitz C, Lange M, Gradl S, Ellermann M, Lienau P, Schreiber SL, Greulich H, Meyerson M..  (2019)  Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.,  10  (11): [PMID:31749907] [10.1021/acsmedchemlett.9b00360]

Source

Source(1):

• Scientific Literature